At a Glance
- Acquirer: LEO Pharma
- Target: Replay
- Deal value: $50 million upfront, plus milestones and royalties
- Focus area: Rare genetic skin diseases
- Lead program: Dystrophic epidermolysis bullosa
What happened?
LEO Pharma entered into a definitive agreement to acquire Replay, a US gene therapy company focused on rare genetic dermatological conditions. The deal gives LEO Pharma Replay’s high-payload herpes simplex virus gene therapy platform and its lead programme for dystrophic epidermolysis bullosa.
Why does it matter?
The acquisition pushes LEO Pharma beyond conventional dermatology and into gene therapy, a move that could create new treatment options for severe inherited skin disorders with few effective therapies. Replay’s platform is designed to deliver large genetic payloads and may be redosable, which could be useful in long-term rare disease management.
Who’s behind it?
LEO Pharma is a Denmark-based dermatology specialist with six decades of experience in skin health. Replay is a gene therapy startup built around an HSV delivery platform, and its leadership says the combination of Replay’s technology with LEO’s dermatology expertise should help bring therapies to patients faster.
How was it achieved?
Replay’s engineered HSV vector was selected because it can carry large genes and has natural tropism for skin cells, making it well suited to dermatologic gene delivery. LEO said it identified Replay through its AI-powered scouting platform, Innoviewer, which it uses to screen for strategic opportunities.
What’s next?
Replay’s equity holders will receive $50 million upfront, along with potential milestone payments and tiered single-digit royalties if programmes reach the market. LEO Pharma will fold Replay’s team and platform into its rare dermatology portfolio as it works to advance the lead DEB programme.